Revolution Medicines closed a public offering of 16.6 million shares, raising $862.5 million for RAS-addicted cancer therapies.Quiver AI SummaryRevolution Medicines, Inc. has successfully completed its...
Revolution Medicines announced a public offering of 14.1 million shares priced at $46 each, aiming for $750 million proceeds.Quiver AI SummaryRevolution Medicines, Inc., a clinical-stage oncology company...
Revolution Medicines provides updates on RMC-6236 and RMC-6291 in clinical trials for RAS-addicted cancers.Quiver AI SummaryRevolution Medicines, Inc. provided a clinical update on its RAS(ON) inhibitor...
Revolution Medicines will host an investor webcast on December 2, 2024, to discuss updates on its RAS(ON) inhibitor portfolio.Quiver AI SummaryRevolution Medicines, Inc., a clinical-stage oncology company...